BioCentury
ARTICLE | Finance

Aug. 10 Quick Takes: Megarounds for Lepu, Dyne; plus CureVac’s IPO plans, top marks for Chinese biotech trio and more 

August 11, 2020 1:16 AM UTC

Riverhead, Ping An lead Lepu’s megaround 
Lepu Biotechnology Co. Ltd. raised RMB1.3 billion ($185.3 million) in a series B round jointly led by Riverhead Capital and Ping An Capital, with participation by Haitong Innovation Capital Management, SDIC, China Reform Holdings’ Central Enterprises Operating Investment Fund and Qingdao Minxin Qiyuan. The company plans to use the funds to support development and launch of its cancer therapies; Lepu has seven programs in the clinic.

CureVac seeking $2.6B valuation in IPO ...